AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04154306 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Red clover
Description: 2 weeks of Red clover
Study NCT04154306 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 weeks of Placebo
Study NCT02776579 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Girls-only resistance training
Study NCT01799317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D2
Description: These patients will receive standard of care vitamin D 1,25 therapy with intervention of vitamin D2
Study NCT04281979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Study Agent
Description: The study agent will be administered via beverages and/or a capsule. The substances used in the study are legal, non-prescription, and are proven safe for human consumption at the doses used. The study agent may be a depressant (such as alcohol), a stimulant (such as caffeine), or an analgesic (such as aspirin).
Study NCT04281979 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In the placebo conditions participants will consume beverages and capsules that contain no or very small quantities of the study agent.
Study NCT03078452 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Power drill
Description: Undergo bone marrow biopsy using power drill
Study NCT03078452 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Jamshidi needle
Description: Undergo bone marrow biopsy using Jamshidi needle
Study NCT00852566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Description: Per oral imatinib 400mg once daily (continuous medication)
Study NCT00852566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Per oral dasatinib 100mg once daily (continuous medication)
Study NCT04125121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane-propofol
Description: General anaesthesia with a maintenance phase of two hours duration with either sevoflurane or propofol.
Study NCT03722095 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active tDCS
Description: A current of 2 milliampère (mA) through electrodes of 5x5cm.
Study NCT02971254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Study NCT03722095 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: Similar set-up as in the active tDCS, but stimulation is too short to cause any effects.
Study NCT03722095 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iTBS
Description: 54 cycles with 10 bursts of 3 pulses, train duration of 2 seconds and intertrain intervals of 6 seconds, results in 1620 pulses at 110% resting motor threshold.
Study NCT03722095 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: iTBS
Description: 54 cycles with 10 bursts of 3 pulses, train duration of 2 seconds and intertrain intervals of 6 seconds, results in 1620 pulses at 110% resting motor threshold.
Study NCT00361114 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sulphadoxine/pyrimethamine
Description: Sulfadoxine/pyremethamine (SP) given as a single dose per manufacturers recommendation (tablets 500mg sulphadoxine and 15mg pyremethamine; child's body weight 5-10Kgs ½ tablet, 11-20Kgs 1 tablet, 21-30 Kgs 1 ½ tablets)
Study NCT00361114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorproguanil/dapsone
Description: Chlorproguanil/ dapsone (CD) given daily for 3 days per manufacturers recommendations (tablets chlorproguanil 15mg/ dapsone 18.75 mg; 5-7.9Kgs 1 tablet, 8-11.9 Kg 1 ½ tablets, 12-15.9 2 tablets, 16-20.9 Kgs 2 ½ tablets, 21- 40Kg 5 tablets).
Study NCT00361114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfadoxine/pyrimethamine
Description: Sulfadoxine/pyremethamine (SP) given as a single dose per manufacturers recommendation (tablets 500mg sulphadoxine and 15mg pyremethamine; child's body weight 5-10Kgs ½ tablet, 11-20Kgs 1 tablet, 21-30 Kgs 1 ½ tablets)
Study NCT02971254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Study NCT04360629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Tranexamic Acid will be given through central vein
Study NCT04360629 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: normal saline will be given through central vein
Study NCT02743169 — intervention group
Intervention type: OTHER
Intervention: Spatially-Optimized
Description: Spatial analysis of retrospective data will be used to optimize the placement of ambulances to decrease response time from the time the call is received until the time the ambulance arrives at the patient's location.
Study NCT01174082 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KLH Vaccine
Description: Donor: 0.5 cc subcutaneously, 3 times on weeks -8, -6 and -2 prior to lymphocyte collection.~Patient: 0.5 cc subcutaneously, 3 times immediately after infusion of donor cells (DLI), and again 4 and 8 weeks post DLI.
Study NCT01174082 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KLH-id Vaccine
Description: Donor: 0.5 cc subcutaneously, 3 times on weeks -8, -6 and -2 prior to donor lymphocyte collection.~Patient: 0.5 cc subcutaneously, 3 times immediately after infusion of donor cells (DLI), and again 4 and 8 weeks post DLI.
Study NCT01174082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 250 mcg/m2 subcutaneously daily for 4 days after each vaccine
Study NCT03935607 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transvaginal sonography
Description: Transvaginal sonography for the evaluation of an amniotic fluid pocket preceding the fetal presenting part.
Study NCT01174082 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apheresis
Description: Day 0 (day of lymphocyte collection) donors undergo a steady state pheresis to obtain lymphocytes.
Study NCT01174082 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Donor Lymphocyte Infusion (DLI)
Description: Day 0, infusion to patient of collected donor cells.
Study NCT04378517 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: psychosocial education in parents groups
Description: psychosocial education
Study NCT04378517 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: psychosocial parents support, interviews with APN
Description: Family strength-oriented therapy conversation
Study NCT02756936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir Zeta
Description: 1 tablet contains 60 mg Daclatasvir
Study NCT02756936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clatazev
Description: 1 tablet contains 60 mg Daclatasvir
Study NCT02880657 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SODB®
Description: Subjects are supplemented with SODB®, daily over 10 weeks. Each volunteer was seen for the 4 visits: - visit of pre-inclusion V1, - visit V2, so-called inclusion visit, - visit V3 after 4 weeks of physical training and - visit V3 after 8 weeks of physical training
Study NCT02880657 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects are supplemented with Placebo, daily over 10 weeks. Each volunteer was seen for the 4 visits: - visit of pre-inclusion V1, - visit V2, so-called inclusion visit, - visit V3 after 4 weeks of physical training and - visit V3 after 8 weeks of physical training
Study NCT02068521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somavaratan
Description: Subcutaneous injection
Study NCT03407430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: During the first chemotherapy cycle, the patient will receive pregabalin 75mg (1 capsule) BID x 4 days before pegfilgrastim 6mg subcutaneous (SC) x1; then pregabalin 150mg (2 capsules) BID x 7 days. During the second chemotherapy cycle, the patient will receive placebo in the same dosing scheme.
Study NCT03407430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: During the first chemotherapy cycle, the patient will receive placebo (1 capsule) BID x 4 days before pegfilgrastim 6mg SC x1; then placebo (2 capsules) BID x 7 days. During the second chemotherapy cycle, the patient will receive pregabalin in the same dosing scheme.
Study NCT01570283 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multivirus-specific T cells Dose Level 1
Description: The feasibility and safety of 3 different dose levels will be evaluated and will determine the maximum tolerated dose (MTD) level.~Dose Level One: 5x10\^6 mCTLs/m2~There may be an option of administering 2 additional doses (at the same level the patient was receiving), 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL.
Study NCT01570283 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multivirus-specific T cells Dose Level 2
Description: The feasibility and safety of 3 different dose levels will be evaluated and will determine the maximum tolerated dose (MTD) level.~Dose Level Two: 1x10\^7 mCTLs/m2~There may be an option of administering 2 additional doses (at the same level the patient was receiving), 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL
Study NCT01086696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FPAC
Description: Each subject will be administered 7 mCi of FPAC,over 10-20 seconds, followed by saline flush.
Study NCT02809885 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis E serology
Study NCT00900497 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: White Blood Cells/Granulocytes
Description: Granulocytes collected by apheresis, cross-matched for ABO-Rh and common antibodies, HLA-mismatched to avoid engraftment
Study NCT02298959 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study NCT02298959 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT02298959 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT02298959 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Elastography
Description: Undergo MRI
Study NCT02298959 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT02298959 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ziv-Aflibercept
Description: Given IV
Study NCT03170518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Description: Canagliflozin 100 mg tablet will be administered orally (by mouth) once-daily.
Study NCT03170518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Description: Canagliflozin 300 mg tablet will be administered orally once-daily.
Study NCT03170518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablet will be administered orally once-daily.
Study NCT01570283 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multivirus-specific T cells Dose Level 3
Description: The feasibility and safety of 3 different dose levels will be evaluated and will determine the maximum tolerated dose (MTD) level.~Dose Level Three: 2x10\^7 mCTLs/m2~There may be an option of administering 2 additional doses (at the same level the patient was receiving), 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL
Study NCT02140866 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand Exercise
Study NCT02140866 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compensatory Intervention Program (CIP)
Study NCT03947736 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: cfDNA was detected by dPCR
Description: Without drug intervention, the patient's peripheral blood was collected and cfDNA was extracted for digital PCR detection.
Study NCT01672944 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TBCCN-developed educational materials
Description: Participants will be asked to view the educational materials developed by TBCCN, in either English or Spanish depending on the RCT in which they are enrolled. These materials include a DVD and a booklet that were developed to enhance community members' understanding and awareness of biospecimen collection and biobanking from healthy individuals.
Study NCT01672944 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: NCI-developed educational materials
Description: Participants will be asked to view the English biobanking educational Brochure entitled Providing your Tissue for Research: What you need to Know, or Spanish brochure entitled Lo que usted debe saber antes de dar sus tejidos para investigación médica.
Study NCT01856361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Description: Angiotensin Converting Enzyme Inhibitor
Study NCT01856361 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Placebo pill that will match the treatment pill
Study NCT05296213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride- potassium iodide
Description: SDF-KI (riva star, SDI.Ltd )was applied ( as a professional application) by micro brush over the early enamel lesions on the buccal surface of molar teeth
Study NCT01298401 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ganitumab
Study NCT01298401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study NCT01298401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study NCT01298401 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Study NCT01224886 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Supervised exercise intervention
Study NCT02216318 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: blue light
Study NCT02216318 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: blue light
Study NCT02418143 — intervention group
Intervention type: DEVICE
Intervention: CorMatrix CanGaroo ECM Envelope
Description: Subjects who have received CorMatrix CanGaroo ECM Envelope for an implantable electronic device placement following a battery change or upgrade.
Study NCT02969993 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: evaluating the voice outcome by the fullfilment of the voice handicap index
Study NCT02251691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advagraf
Description: Compare the drug compliance between once daily or twice daily regimen
Study NCT02251691 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: Compare the drug compliance between once daily or twice daily regimen
Study NCT02496819 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meta-cognitive self-regulated learning intervention
Description: It is a 12-week intervention programme with one 60 minutes sessions per week.
Study NCT02496819 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensory integration intervention
Description: It is a 12-week intervention programme with one 60 minutes sessions per week.
Study NCT02496819 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Activity-based intervention
Description: It is a 12-week intervention programme with one 60 minutes sessions per week.
Study NCT03828136 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novum Vitrium® Cervical Interbody Device
Description: For spinal fusion procedure at one level (C3 to T1) of the cervical spine.
Study NCT03828136 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Allograft Ring or Block
Description: Standard of Care
Study NCT03090997 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: vitamin C (500 mg / day) + placebo
Description: Adminstration of vitamin C (500 mg / day/orally) + placebo (same presentation like resveratrol)
Study NCT03090997 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: resveratrol (500 mg / day) + placebo
Description: Adminstration of resveratrol (500 mg / day/orally) + placebo (same presentation like vitamin C)
Study NCT01643460 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 98% Ethanol & Paclitaxel injection
Description: Pancreatic cyst injection via Endoscopic Ultrasound (EUS)of 98% Ethanol with Paclitaxel (dose determined in relation to cyst size \& amount of fluid aspirated from the cyst.
Study NCT05296213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casein phosphopeptide amorphous calcium phosphate
Description: CPP-ACP (tooth mousse, GC, Matraville Sydney, Australia) was applied by using micro brush over the early enamel lesions on the buccal surface of the molar teeth twice daily. the patients were instructed to leave it for about 3minutes before rinsing
Study NCT05296213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: experimental tricalcium silicate
Description: prepared tricalcium silicate paste was applied by using micro brush over the early enamel lesions on the buccal surface of the molar teeth twice daily. the patients were instructed to leave it for about 3minutes before rinsing
Study NCT03308292 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Aerobic exercise program
Study NCT00371787 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft contact lens
Description: Soft contact lens
Study NCT01240434 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trocar site closure
Description: The study has 2 arms: one in which all the ST orifices are closed by suturing the external fascia of the abdominal wall with a number 1 monofilament absorbable suture (Polydioxanone) (Group A), and another in which all the orifices of the ST are left open, closing only the skin (Group B).
Study NCT01240434 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Trocar site closure
Description: The study has 2 arms: one in which all the ST orifices are closed by suturing the external fascia of the abdominal wall with a number 1 monofilament absorbable suture (Polydioxanone) (Group A), and another in which all the orifices of the ST are left open, closing only the skin (Group B).
Study NCT00972075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melatonin (Circadin)
Description: 2 mg prolonged release melatonin tablets once daily 2 hours before going to bed
Study NCT00972075 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one tablet per day 2 hours before going to bed
Study NCT00919594 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy for Mothers (IPT-MOMS)
Description: Interventions will be administered during the 3 Month Acute Randomized Phase and will consist of nine individual 45-minute sessions conducted over the course of three months. Treatment cannot exceed nine sessions. In addition to standard IPT techniques, IPT-MOMS includes a specific focus on the challenges associated with managing a child who suffers from psychiatric problems.
Study NCT00919594 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Supportive Psychotherapy
Description: Interventions will be administered during the 3 Month Acute Randomized Phase and will consist of nine individual 45-minute sessions conducted over the course of three months. Treatment cannot exceed 9 sessions. Brief supportive therapy (BSP) is a manualized form of supportive psychotherapy which emphasizes reflective listening and elicitation of affect (Markowitz et al., 2008). Therapists are instructed to allow patients to determine the focus of each session, pulling for emotion, validating emotions when possible, and offering empathic comments.
Study NCT00687856 — intervention group
Intervention type: PROCEDURE
Intervention: Echocardiogram (echo)
Description: Participants will undergo a series of echoes to determine if they are eligible to be weaned from LVAD support. Each echo exam will involve the use of an ultrasound probe on the chest of participants to assess the pumping ability of their hearts.
Study NCT01418794 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High dose rapamycin stent
Description: Concentration of rapamycin is 2.5%
Study NCT01418794 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low dose rapamycin stent
Description: Concentration of rapamycin is 1.5%
Study NCT01470508 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Individuals meet with a therapist once a week for 25 sessions, 50 minutes in length, for a period of 27 weeks for therapy. Cognitive Behavioral Therapy is manualized and is the standard form of care at the UNC Eating Disorders Program.
Study NCT01470508 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy with Family Enhancement
Description: Individuals will meet with a therapist once a week for 25 sessions, 50 minutes in length, for a period of 27 weeks for therapy. Cognitive Behavioral Therapy with Family Enhancement is manualized and will involve the participation of family members during six (6) weeks of treatment.